FDA suggests ZYN nicotine pouches may be safer than cigarettes

Key Points:

• The FDA has authorized Swedish Match USA, part of Philip Morris International, to market 20 ZYN nicotine pouch products as posing lower risks of serious diseases like mouth cancer and heart disease compared to cigarettes.
• Nicotine pouches, which deliver nicotine without burning tobacco, contain up to 6 mg of nicotine but are not FDA-approved smoking cessation aids; experts warn about the addictive potential of their higher nicotine levels.
• The FDA's authorization covers select ZYN flavors and strengths, excluding fruity flavors popular among youth, amid concerns over youth usage rates, with 1.7% of middle and high school students reporting nicotine pouch use in 2025.
• Public health advocates, including the American Lung Association, strongly oppose the FDA's decision, fearing it could increase youth addiction to nicotine, and have called for the authorization to be reversed.
• The FDA requires Swedish Match to monitor consumer risk perceptions and youth usage over five years and retains the authority to revoke the authorization if youth use significantly increases.